Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6955501 | 0.86 | LTC4S (0.63) | ALDH1A1LMNAALOX12KDM4ENPSR1 | |
| SCHEMBL6953534 | 0.85 | RAB9A (0.50) | ALDH1A1LMNAALOX12KDM4ENPSR1 | |
| SCHEMBL6963003 | 0.85 | ALDH1A1 (0.54) | ALDH1A1LMNAALOX12KDM4ERAB9A | |
| SCHEMBL7845144 | 0.85 | SMN1; SMN2 (0.50) | ALDH1A1LMNAALOX12NPSR1RAB9A | |
| SCHEMBL6963618 | 0.80 | CYP1A2 (0.50) | ALDH1A1LMNAKDM4ERAB9ANPC1 | |
| SCHEMBL6284560 | 0.80 | NPC1 (0.56) | ALDH1A1LMNANPSR1RAB9ANPC1 | |
| SCHEMBL2682040 | 0.78 | RAB9A (0.71) | ALDH1A1LMNAALOX12KDM4ENPSR1 | |
| SCHEMBL10872503 | 0.75 | KDM4E (0.41) | ALDH1A1LMNAALOX12KDM4ENPSR1 | |
| SCHEMBL4364365 | 0.75 | NPSR1 (0.63) | ALDH1A1LMNAALOX12KDM4ENPSR1 | |
| SCHEMBL6959647 | 0.73 | ALDH1A1 (0.53) | ALDH1A1LMNAALOX12KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1064263-B1 | NONNUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE FOR THE TREATMENT OF HIV-INFECTION | PARKER HUGHES INST (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6925388-B1 | Heterocyclic nonnucleoside inhibitors of reverse transcriptase | PARKER HUGHES INSTITUTE (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050153995-A1 | Nonnucleoside inhibitors of reverse transcriptase, composite binding pocket and methods for use thereof | PARKER HUGHES INSTITUTE (US) | 2005-07-14 | — | — | US | disclosed |
| EP-1528057-A1 | Nonnucleoside inhibitors of reverse transcriptase for the treatment of HIV infection | Parker Hughes Institute (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1194427-B1 | THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV | PARKER HUGHES INST (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6380190-B1 | ALSO INHIBIT REPLICATION OF RETROVIRUS SUCH AS HUMAN IMMUNODEFICIENCY VIRUS-1 | PARKER HUGHES INSTITUTE | 2002-04-30 | — | — | US | disclosed |
| EP-1194427-A1 | THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV | Parker Hughes Institute (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6300351-B1 | FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) REVERSE TRANSCRIPTASE | PARKER HUGHES INSTITUTE | 2001-10-09 | — | — | US | disclosed |
| US-6180654-B1 | THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS; RETROVIRUS | WAYNE HUGHES INSTITUTE | 2001-01-30 | — | — | US | disclosed |
| EP-1064263-A2 | NONNUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE FOR THE TREATMENT OF HIV-INFECTION | Parker Hughes Institute (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000078756-A1 | THIOPHENE-ETHYL THIOUREA COMPOUNDS AND THEIR USE IN THE TREATMENT OF HIV | PARKER HUGHES INSTITUTE (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078755-A1 | THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV | PARKER HUGHES INSTITUTE (US) | 2000-12-28 | — | — | WO | disclosed |
| US-6156759-A | Nonnucleoside inhibitors of reverse transcriptase, composite binding pocket and method for use thereof | PARKER HUGHES INSTITUTE (US) | 2000-12-05 | — | — | US | disclosed |
| US-6124307-A | INHIBIT REPLICATION OF RETROVIRUS, SUCH AS HUMAN IMMUNODEFICIENCY VIRUS-1 | WAYNE HUGHES INSTITUTE (US) | 2000-09-26 | — | — | US | disclosed |
| US-6124324-A | AN ENZYME INHIBITOR OF REVERSE TRANSCRIPTASE FOR THE TREATMENT OF HIV INFECTION, INCLUDING MUTANT, DRUG-SENSITIVE, DRUG-RESISTANT, AND MULTI-DRUG RESISTANT STRAINS OF HIV | HUGHES INSTITUTE (US) | 2000-09-26 | — | — | US | disclosed |
| US-5998411-A | VIRICIDES | HUGHES INSTITUTE (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999047501-A2 | NONNUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE FOR THE TREATMENT OF HIV-INFECTION | PARKER HUGHES INSTITUTE (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153995-A1 | Nonnucleoside inhibitors of reverse transcriptase, composite binding pocket and methods for use thereof | DNTT, NUDT1, NAPRT | ALDH1A1 2019/4885LMNA 4379/4885ALOX12 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.